Market Signal Briefing

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

So what: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the PomDoctor class action, go to https://rosenlegal.com/submit-form/?case_id=52621 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) PomDoctor was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) PomDoctor's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about PomDoctor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the PomDoctor class action, go to https://rosenlegal.com/submit-form/?case_id=52621 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Picard Medical, Inc. (NYSE American: PMI) between September 2, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Picard Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Picard Medical class action, go to https://rosenlegal.com/submit-form/?case_id=52263 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Picard's business, operations, and the true nature of its securities trading throughout the Class Period. Specifically, defendants failed to disclose to investors that: (1) Picard was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Picard's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about Picard's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the Picard Medical class action, go to https://rosenlegal.com/submit-form/?case_id=52263 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288568

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Trawick-Images / iStock via Getty Images

Albertsons (NYSE:ACI) just reported Q3 FY2026 earnings showing identical sales growth of 2.4% driven almost entirely by pharmacy. H&R Block (NYSE:HRB) posted Q2 FY2026 results with revenue of $198.87 million, up 11.1% year over year. Two different businesses, both flying under the radar, both leaning into technology to defend their turf.

Pharmacy Carries Albertsons. Tax Season Is Starting to Carry H&R Block. Albertsons beat on the bottom line, posting adjusted EPS of $0.72 against a consensus of $0.68. Pharmacy is doing the heavy lifting on identical sales while compressing margins. Gross margin slipped to 27.4% from 27.9% the prior year because pharmacy is lower-margin than center-store groceries. Digital sales grew 21% year over year, and loyalty membership hit 49.8 million members, up 12%. New CEO Susan Morris framed the strategy: “Our investments in technology and AI are fundamentally reshaping how we operate and serve our customers; driving smarter decisions, greater efficiency, and more personalized experiences.”

H&R Block’s Q2 is always a loss quarter — tax season hasn’t peaked yet. But off-season results were strong. Assisted tax prep revenue jumped 15.6% year over year, DIY software climbed 22.3%, and Wave, the small business platform, grew 12.1%. New CEO Curtis Campbell set the tone: “In a year of heightened uncertainty for many filers, our client-first strategy and disciplined execution keep us focused on durable growth and long-term value.”

Business Driver Albertsons (ACI) H&R Block (HRB) Primary Growth Engine Pharmacy + digital loyalty Assisted tax prep + Wave AI Focus Personalization, efficiency Expert-led tax experience Key Headwind Medicare drug pricing (IRA) AI-native competitors Capital-Intensive Grocer vs. Cash-Generating Machine Albertsons is spending $1.8 billion to $1.9 billion in capital expenditures this fiscal year on store remodels and digital infrastructure. H&R Block generated $598.85 million in free cash flow in FY2025 on a fraction of Albertsons’ revenue. That asset-light model funds an aggressive buyback program — 47% of shares outstanding repurchased since 2016. Albertsons expanded its repurchase program to $2.75 billion, but carries a net debt ratio of 2.29x, up from 1.88x a year ago. H&R Block carries negative shareholders’ equity of -$823 million — a byproduct of returning more cash than it retains, not a sign of distress.

Consumer sentiment at 56.4 on the University of Michigan index, well below the 80 neutral threshold, supports both businesses. Stressed consumers don’t stop buying groceries or filing taxes.

The Next Test: Pharmacy Pricing and Tax Season Volume For Albertsons, the Medicare Drug Price Negotiation Program is the number to watch. Management flagged a 65 to 70 basis point drag on Q4 identical sales from this program alone — a structural headwind, not a one-quarter blip. For H&R Block, the question is whether AI-native competitors are taking clients or just generating headlines. The 15.6% growth in assisted tax prep revenue suggests the human-plus-AI model is holding up.

Valuation and Key Metrics to Watch H&R Block is down 29% year to date while growing revenue at double digits. Key metrics to follow include free cash flow trends and share count reduction at H&R Block, and whether the digital loyalty flywheel and pharmacy network at Albertsons develop into durable competitive advantages.

If You have $500,000 Saved, Retirement Could Be Closer Than You Think (sponsor) Retirement can be daunting, but it doesn’t need to be. Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter! Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality. (sponsor)

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.

Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and statistical analysis, along with the primary data set provided in the original submission, appropriately addresses the Complete Response Letter3.

Given the potential to address significant unmet medical need, TLX101-Px has been granted Orphan Drug4 and Fast Track5 designations by the FDA. PET imaging with 18F-FET is already included in international clinical practice guidelines for the imaging of gliomas6, however there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging commercially available in the U.S.

Dr. David N. Cade, Telix Group Chief Medical Officer, said, “We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.”

Maggie Haynes, Executive Director, Head for the Cure Foundation, added: “Our community is encouraged by the FDA’s ongoing engagement and guidance to the sponsor and support for the Expanded Access Program for TLX101-Px. We are hopeful of an expedited review, so this important and proven imaging option can become available to those who urgently need it.”

About TLX101-Px

TLX101-Px is a PET imaging agent, which has been granted fast track and orphan drug designations by the FDA as an imaging agent for the characterization of recurrent or progressive glioma from treatment related changes. TLX101-Px targets membrane transport proteins known as LAT1 and LAT27. This enables TLX101-Px to be potentially utilized as a companion diagnostic agent to TLX101-Tx (iodofalan 131I), Telix’s LAT1-targeting glioblastoma (GBM) therapy candidate, currently under investigation in the pivotal IPAX-BrIGHT study8. 

About gliomas in the U.S.

Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) neoplasm that originates from glial cells, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors9. In the U.S., there are six cases of gliomas diagnosed per 100,000 people every year10. GBM is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.11. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients12, with an expected survival duration of 12-15 months from diagnosis13. 

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, with the goal to address significant unmet medical needs in oncology and rare diseases. With international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is headquartered in Melbourne, Australia. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA14. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
[email protected]

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

1 Brand name subject to final regulatory approval.
2 Positron emission tomography.
3 Telix ASX disclosure April 28, 2025.
4 Telix ASX disclosure October 6, 2020.
5 Telix ASX disclosure April 16, 2024. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. More: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
6 Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V1.2025.
7 L-type amino acid transporters 1 and 2.
8 ClinicalTrials.gov ID: NCT07100730.
9 Goodenberger et al. Cancer Genet. 2012.
10 Mesfin et al. StatPearls. 2024.
11 Ostrom 2022, CBTRUS (Central Brain Tumor Registry of the United States) Statistical Report.
12 Park et al. Journal of Clinical Oncology. 2010.
13 Ostrom et al. Neuro Oncol. 2018.
14 Telix ASX disclosure March 21, 2025.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Richtech (RR) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Richtech securities between January 27, 2026 and 12:00 PM EST on January 29, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, March 15, 2026 (GLOBE NEWSWIRE) --

What’s Happening?

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ:RR) in the The United States District Court for the District of Nevada on behalf of all persons and entities who purchased or otherwise acquired Richtech securities between January 27, 2026 and 12:00 PM EST on January 29, 2026, both dates inclusive (the “Class Period”). Investors have until April 3, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Richtech claimed that it had a collaborative and commercial relationship with Microsoft when it did not; and (2) as a result, defendants’ statements about Richtech’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.On January 29, 2026, Investing.com published an article entitled “Richtech Robotics stock tumbles after Hunterbrook questions Microsoft deal.” The article stated that Richtech stock plunged “amid broader market weakness and a critical report from Hunterbrook questioning the company’s recently announced Microsoft collaboration.”On this news, Richtech common stock fell 20.87% on January 29, 2026. What are the Next Steps?

If you purchased or otherwise acquired Richtech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant (IMVT 2.32%), an estimated $24.53 million trade based on quarterly average pricing.

Logos bought 1,100,000 additional shares of Immunovant, a transaction estimated at $24.5 million based on average quarterly closing prices.The full position grew by roughly $6.1 million in total value over the quarter, reflecting both the new shares and price movement in the stock.Logos finished the quarter holding 1,375,000 Immunovant shares, valued at roughly $34.95 million which represents 2.11% of the fund’s AUM, placing it outside the fund’s top five holdingsWhat happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Logos Global Management LP increased its position in Immunovant by 1,100,000 shares during the fourth quarter of 2025. The estimated transaction value was $24.4 million, based on the average closing price in the quarter. The value of the stake at quarter-end rose by $6.1 million, a figure that includes both trading and market price effects.

What else to knowAfter the buy Immunovant accounts for 2.11% of the fund’s 13F assets under management (AUM)Top holdings after the filing:NASDAQ:RVMD: $238.50 million (14.4% of AUM)NASDAQ:PRAX: $110.53 million (6.7% of AUM)NASDAQ:IDYA: $108.03 million (6.5% of AUM)NASDAQ:OLMA: $80.22 million (4.9% of AUM)NASDAQ:CDTX: $68.48 million (4.1% of AUM)As of March 13 2026, shares of Immunovant were priced at $24.72, up 29.3% over the past year and outperforming the S&P 500 by 10.58%.Company OverviewMetricValuePrice (as of market close 3/13/26)$24.70Market Capitalization$5.03 billionNet Income (TTM)($464.20 million)1-Year Price Change29.24%Company SnapshotImmunovant is a subsidiary of Roivant Sciences (NASDAQ: ROIV) focused on monoclonal antibody therapeutics for autoimmune diseases.What this transaction means for investorsIts lead candidate, batoclimab, has completed Phase III trials in myasthenia gravis and is in ongoing Phase III trials for thyroid eye disease, with results expected in the first half of 2026.The company has no approved products yet — revenue depends entirely on successful clinical and regulatory outcomes.Immunovant is advancing batoclimab across multiple autoimmune indications, with no approved products yet and a regulatory path that hinges on ongoing Phase III outcomes.

What This Transaction Means for InvestorsLogos Global Management is a San Francisco-based, healthcare-focused hedge fund running a concentrated, research-driven book in life sciences and biotech. This isn't a generalist fund dipping into the sector — it's the kind of firm that does deep scientific and regulatory diligence before sizing up a position.

The Immunovant buy is notable for its scale. Logos nearly quintupled its stake, adding 1.1 million shares for an estimated $24.5 million and bringing its total to roughly $35 million. That's a meaningful commitment: Immunovant now sits at about 2% of AUM, up from 0.4% — a shift that carries real weight in a concentrated book.

For individual investors, a move like this from a specialist healthcare fund is worth treating as a research prompt rather than a buy signal. Clinical-stage biotech carries real binary risk, and institutional conviction here is usually the product of diligence retail investors don't have direct access to. The more useful takeaway is simply that a fund that lives in this space saw enough to add aggressively — why exactly, and how it fits their broader strategy, is hard to know without explicit statements from them. What investors can watch is the batoclimab thyroid eye disease readout, with topline data from both Phase 3 TED studies expected concurrently in the first half of 2026. That's the next concrete event that will shape Immunovant's regulatory path.

Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.

Investors have cheered for the success of American Express (AXP 0.57%). In the past five years, shares in the premium credit card company have produced a total return of 124% (as of March 10), lifted by steady financial gains. However, the market has tanked the share price 18% just this year.

There might be fears about the negative impact artificial intelligence will have on the job market and consumer spending behavior. The latest research from The Motley Fool highlights how professions that handle repetitive tasks are at risk of being automated over the next decade.

The worries for American Express seem overblown right now, though. The best investors consider opportunities not based on the latest news but with a long-term mindset. Does this stock have what it takes to be a millionaire maker?

Image source: The Motley Fool.

American Express operates from a position of strength American Express had a strong showing in 2025. Revenue (net of interest expense) jumped 10% year over year to $72.2 billion. This growth occurred at a time when the economy is in a state of heightened uncertainty. Payment volume rose by 7% to $1.7 trillion, showcasing the scale that American Express has achieved.

Younger consumers are flocking to the company's offerings. "As of Q4, millennial and Gen Z customers now make up the largest share of U.S. consumer spending, and they remain the fastest-growing cohorts," CFO Christophe Le Caillec said on the Q4 2025 earnings call.

This is undoubtedly an encouraging trend to pay attention to. When it comes to winning over this valuable cohort, American Express is competing effectively not only against its traditional peers but also with more nimble fintech enterprises. Younger consumers naturally have a longer lifetime value, so starting that relationship early on is important for the business.

The company registered diluted earnings per share of 10% in 2025. And over the long term, the leadership team is targeting a mid-teens growth rate. American Express will lean on its strong brand presence and ability to increase payment volume, the number of active cards, and card fees to drive ongoing success.

Today's Change

(

-0.57

%) $

-1.72

Current Price

$

300.17

Investors can capture a better valuation It's clear that American Express is a high-quality business. That should put it on your radar as a possible portfolio addition.

Even better is the current offer from the market, which makes now a potentially worthwhile time to scoop up shares. The stock trades at a forward price-to-earnings ratio of 17.5. I don't view this as being an obvious bargain opportunity. However, if you've been waiting on the sidelines for a compelling entry point, now is your chance to make a move.

But just because American Express looks attractive at the current price doesn't mean that this is a millionaire-making financial stock. To fall into this bucket, there has to be a possibility that the shares can skyrocket 50-fold or 100-fold in the future. That's not going to happen with this business.

American Express is an advertising partner of Motley Fool Money. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Up until 2026, the S&P 500 (^GSPC 0.61%) spent years as the class of the U.S. equity market. Powered by the "Magnificent Seven" stocks and the artificial intelligence (AI) boom, large caps were where investors found the best returns.

But the market may finally be turning. The tech sector is in the red for the year, while value, defensive, dividend, and small-cap stocks are outperforming. Investors are considering whether AI spending has gotten out of control and valuations on pricey megacap growth stocks have gotten a little too high, given conditions.

If your portfolio is still heavy in the S&P 500 or Nasdaq-100, it might be time to look elsewhere for better opportunities. Here are two ETFs that I believe are primed to outperform the S&P 500 over the next several years.

Image source: Getty Images.

1. iShares Core S&P Small-Cap ETF Over the past few years, small companies have struggled to grow earnings. They were first hit by high inflation and then again by tariffs on imported goods. The S&P 600 Small Cap index experienced 11 straight quarters of negative year-over-year earnings growth from 2022 to early 2025.

That trend is finally beginning to reverse. The index returned to positive earnings growth in the second quarter of 2025. In late 2026, it's forecast to deliver a higher earnings growth rate than the S&P 500. If that expectation holds, small caps could soon deliver above-average earnings growth at a price-to-earnings (P/E) ratio that's more than 30% lower than that of the large-cap index.

The iShares Core S&P Small-Cap ETF (IJR 0.12%) tracks the S&P 600 index and is poised to capitalize on this development. And with an expense ratio of just 0.06%, it's one of the cheapest ways to access it.

Today's Change

(

-0.12

%) $

-0.15

Current Price

$

122.05

2. Vanguard Mid-Cap ETF If you believe in the small-cap story, the mid-cap story isn't much different. It could probably be considered a literal middle ground between small and large companies, where earnings growth rates look compelling and P/E ratios fall somewhere in between.

Today's Change

(

-0.05

%) $

-0.14

Current Price

$

289.00

The other big advantage of moving into mid caps here is how much different the index looks than the S&P 500. Industrials is the largest sector holding at roughly 20% of assets. After that, consumer discretionary, financials, and technology are all at around 13% to 15%. That creates a much more diversified portfolio that's less reliant on just the tech sector or a handful of companies.

The Vanguard Mid-Cap ETF (VO 0.05%) follows the CRSP US Mid Cap Index, a cap-weighted basket of roughly 300 stocks within a specific market cap range. In true Vanguard fashion, its 0.03% expense ratio is among the lowest in this space while remaining highly liquid and tradable.

David Dierking has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard Mid-Cap ETF and iShares Core S&P Small-Cap ETF. The Motley Fool has a disclosure policy.

Artificial intelligence (AI) stocks have taken a bit of a beating in recent months, as investors question the high valuations after a three-year bull market and the true return that all of the AI investment is actually generating.

For some AI stocks, the cautious reaction is spot on, but for others, it is not.

But what's happening is that some AI stocks that are truly driven by the AI boom and will continue to flourish are being caught up in the sell-off -- and that's actually good news for investors. That means that some great AI stocks can be scooped up at lower and quite reasonable valuations.

Image source: Getty Images.

The one that I would scoop up first is Nvidia (NVDA 1.56%). Some would argue that you could never go wrong adding shares of Nvidia, even at its all-time highs. But now, with the stock price down about 5% since late February to $184 per share, it is a particularly great time.

The bull case for Nvidia Making the bull case for Nvidia is not hard -- it's the valuation case where the rubber meets the road.

Nvidia is the most dominant player by far in making graphics processing units (GPUs) for computers of all types. But its major focus is on making AI chips for high-performance computers and data centers.

Nvidia's AI chips have a massive 90% market share within the data center market. And with the demand for AI computing only increasing and the proliferation of data centers, Nvidia's chips will be in high demand for years to come.

Today's Change

(

-1.56

%) $

-2.87

Current Price

$

180.28

The growth numbers continue to be staggering, as Nvidia grew revenue 73% and earnings 98% year over year last quarter. Data center revenue made up 91% of the $68 billion in revenue for the fiscal fourth quarter, which ended Jan. 25.

In the first quarter, the company expects revenue to grow another 15% over Q4 to $78 billion. And during its fiscal Q3 earnings call, officials said the company had some $500 billion in orders to be executed through the end of calendar year 2026, so it's just a massive amount of revenue that is continuing to pour in.

As I said, its not a question of making the bull case, but the valuation case, and Nvidia wins there, too.

The valuation case for Nvidia The stock trades at 37 times earnings, but its forward P/E, based on earnings projections for the next 12 months, is just 22 -- very reasonable if not downright cheap. Analysts expect Nvidia to increase revenue by 70% and earnings by 73% this fiscal year.

That valuation truly makes Nvidia a slam dunk buy right now. Some 93% of Wall Street analysts agree. The stock has a median price target of $265 per share, which would suggest a 43% return over the next 12 months.

If you had $1,000 to invest in an AI stock, that could buy you around five shares of Nvidia. There probably aren't too many better places to park your money.

When Warren Buffett stepped down as CEO of Berkshire Hathaway (BRKA 0.24%)(BRKB 0.38%) at the end of 2025, he left behind a gargantuan war chest worth $373.3 billion. He also spent his last few years as CEO being a net seller of stock, trimming Berkshire's massive investment portfolio even as the S&P 500 hit record highs.

Why would the "Oracle of Omaha" have been so seemingly cautious when so much of Wall Street is all in on the current bull run?

Image source: Getty Images.

The numbers tell a striking story Berkshire sold approximately $134 billion in equities during 2024 alone while the bull market raged. The selling continued through 2025, with Berkshire slashing its Apple position repeatedly, trimming Bank of America, and cutting its Amazon stake by 77% in the fourth quarter.

And during the same period, Buffett steadily grew his company's war chest. From 2022 through today, Berkshire's cash and short-term investments increased from $128.6 billion to today's $373.3 billion. You can see the rapid growth in the chart below.

BRK.B Cash and Short Term Investments (Quarterly) data by YCharts

Buffett's attitude In his second-to-last annual letter to shareholders, Buffett compared the modern stock market to a casino, writing that markets exhibit "far more casino-like behavior" than when he was young and that their active participants are "neither more emotionally stable nor better taught." He warned of Wall Street's affinity for "feverish activity" and reaffirmed that Berkshire would "never risk permanent loss of capital."

It would seem that Buffett was concerned by what he saw: artificial intelligence (AI) fueled euphoria, an increasing willingness from investors to pay a premium for the possibility of future returns, global instability, and stocks trading at extreme levels.

The theory If Buffett saw signs of a coming "conflagration," as he calls market meltdowns, it would make sense for him to play defense -- locking in profits from his investments and growing his cash reserves. That's not just caution for the sake of caution. It's a playbook that has served him extraordinarily well.

During the 2008 financial crisis, Buffett deployed roughly $14.5 billion across deals with Goldman Sachs, what was then General Electric, and Bank of America. Because he was one of the few investors with both capital and nerve, he was able to negotiate terms that were only available after a crash. The Goldman deal alone -- $5 billion in preferred shares at a 10% dividend plus warrants -- generated around $3.1 billion in returns. His Bank of America warrants eventually became a $12 billion gain.

The counterargument Of course, there are more generous interpretations of Buffett's defensive posture. By leaving his successor, Greg Abel, with an unprecedented war chest, Buffett may have given him the widest possible runway to define his own legacy. Abel's first shareholder letter emphasized exactly that flexibility, writing that Berkshire's "substantial liquidity" enables it to "respond swiftly when opportunities arise."

Today's Change

(

-0.38

%) $

-1.89

Current Price

$

490.00

There's also the straightforward math problem. Berkshire is so enormous that very few investments can meaningfully move the needle. Accumulating cash may simply be the default when you manage hundreds of billions of dollars and refuse to overpay.

And even if Buffett does see a crash on the horizon, we shouldn't forget that he's human. He's made mistakes -- the Kraft Heinz acquisition and selling airline stocks at pandemic lows, to name a couple. He's an incredibly successful investor, but he's not infallible.

What it means for you At the end of the day, I can't know his thinking -- not for certain -- but I do think Buffett had serious concerns about the market before he stepped down.

That doesn't mean you need to sell everything. Rather, take a hard look at your portfolio and ask yourself whether you believe in the companies you own and their ability to survive and thrive on the other side of a major correction. And maintaining a cash position, as Buffett has demonstrated time and again, is a great way to take advantage of opportunities when they arise.

Bank of America is an advertising partner of Motley Fool Money. Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Apple, Berkshire Hathaway, and Goldman Sachs Group and is short shares of Apple. The Motley Fool recommends Kraft Heinz. The Motley Fool has a disclosure policy.

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?

Affected uniQure N.V. Investor Summary

Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Huntington’s disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to investor RADNOR, Pa., March 15, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) (uniQure) on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive (the Class Period). This action, captioned Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed in the United States District Court for the Southern District of New York.

Important Deadline Reminder: Investors who purchased or otherwise acquired uniQure ordinary shares during the Class Period may, no later than April 13, 2026, move the Court to serve as lead plaintiff for the class.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired uniQure ordinary shares and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:

(484) 270-1453
[email protected]
https://www.ktmc.com/qure-uniqure-nv-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=qure&mktm=PR

There is no cost or obligation to speak with an attorney.

Learn more about uniQure N.V. on YouTube:

uniQure N.V. Securities Class Action Lawsuit (long video)uniQure N.V. Securities Class Action Lawsuit (short video) UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington’s disease (HD). uniQure’s leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure misled investors about its Phase I/II clinical trials (Pivotal Study) of AMT-130 as well as the prospects and timeline of uniQure’s Biologics License Application (BLA) submission to the FDA for approval to use AMT-130 to treat patients with HD.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about uniQure’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants’ statements about uniQure’s business, operations, and prospects lacked a reasonable basis.

Why did uniQure’s Share Price Drop?
Investors learned the truth about the company’s prospects and the BLA timeline for AMT-130 on November 3, 2025, when uniQure revealed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.” Although the Company “plan[ned] to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130,” uniQure admitted that “the timing of the BLA submission for AMT-130 is now unclear.” On this news, the price of uniQure ordinary shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.

WHAT QURE INVESTORS CAN DO NOW:

File to be lead plaintiff by April 13, 2026.Contact KTMC for a free case evaluation.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR UNIQURE N.V. INVESTORS:
uniQure investors may, no later than April 13, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages uniQure investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California.  KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.   The complaint in this matter was filed by KTMC.

CONTACT:

Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

        May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

HomeStock IdeasQuick Picks & Lists

SummaryThe Touchstone Mid Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell MidCap® Index, for the quarter ended December 31, 2025.Both stock selection and sector exposure were tailwinds to relative performance.Underweight Utilities and overweight Materials helped performance.Underweight Information Technology and overweight Consumer Staples detracted from performance. tadamichi/iStock via Getty Images

The following segment was excerpted from the Touchstone Mid Cap Fund Q4 2025 Commentary.

Portfolio Review The Touchstone Mid Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell MidCap® Index, for the quarter ended December 31, 2025.

14 Followers

HONG KONG, HK / ACCESS Newswire / March 15, 2026 / SINOPEC Engineering (Group) Co., Ltd. ("SEG" or the "Company", together with its subsidiaries collectively known as the "Group") (stock code: 2386) today announced its annual results for the twelve months ended 31 December 2025 (the "Reporting Period").

In 2025, facing the challenges of profound shifts in the global energy landscape and intensifying industry competition, the Group consistently prioritized high-quality development as the overarching principle. We have advanced international operations with greater openness, driven technological innovation with unwavering determination, and rewarded shareholder trust with pragmatic measures-delivering a solid annual performance.

In 2025, the Company achieved operating revenue of RMB70.074 billion and net profit of RMB1.807 billion. The Board consistently adheres to the core principle of "investor-centricity," sharing the fruits of high-quality development with all shareholders through a high dividend policy. A final dividend for 2025 of RMB0.104 per share is proposed, representing a base dividend payout ratio of 65% for the full year. To further demonstrate unwavering confidence in long-term development and safeguard shareholder returns, the Company initiated our first special dividend distribution, proposing an additional special dividend of RMB0.094 per share, resulting in a total distribution of RMB0.198 per share with the final dividend on a combined basis. Including the interim dividend already paid, the total dividend per share for the whole year amounts to RMB0.358, representing an effective payout ratio of 88%, maintaining the same dividend per share as last year.

Operational quality and efficiency were steadily improved, while development resilience continues being strengthened.

Market scale maintained steady growth. New orders signed throughout the year reached RMB101.248 billion, remaining above the RMB100 billion mark for the second consecutive year, which demonstrates a positive trend of "steadily increasing total volume, continuously optimized structure, and accelerated expansion into front-end business segments." International operations improved in both quality and speed, establishing a diversified and balanced layout where Sinopec markets, non-Sinopec markets and international markets each account for one-third of the portfolio, significantly enhancing risk resilience. Breakthroughs were achieved in high-end business segments. The high-level front-end engineering advantage was further consolidated, with the successful signing of landmark overseas front-end projects such as the FEED+ convertible EPC contract for the Saudi ACWA large-scale green hydrogen project. All five engineering subsidiaries achieved their first overseas front-end business contracts within the year, comprehensively enhancing source competitiveness. Comprehensive strengths have become more apparent. The unique competitive advantage of "Global Rules + Chinese Efficiency" has been fully demonstrated, with our integrated engineering service capabilities earning high recognition from global clients. Currently, front-end and EPC contracts account for over 80% of our order backlog, and the order structure continues to optimize, effectively stimulating the continuous optimization of the revenue structure, demonstrating strong operational resilience in intense market competition and achieving both qualitative enhancement and reasonable quantitative growth.

Technological innovation capabilities remain at the forefront, driving significant progress in new industrialization.

Steady progress in technology-driven value creation. Throughout the year, technology development and licensing contracts totaling RMB1.013 billion were signed, demonstrating a steady enhancement in the direct efficiency-generating capacity of technology. The innovation ecosystem has expanded comprehensively. Adhering to the principles of "open cooperation and integrated innovation", we deepened industry-academia-research integration with top research institutes and universities, and collaborated with overseas clients and partners to promote the global deployment of our leading technologies. We successfully hosted the 12th World Congress of Chemical Engineering SubForum 12 on "Process Industry Innovation and Process System Engineering Reinvention", gathering nearly 200 global experts, scholars, corporate representatives, and industry elites in the chemical engineering eld for exchange of insights. Accelerating implementation of digital and intelligent transformation. The "Guidelines for Comprehensively Advancing the Company's Leadership in the New Industrialization of the Engineering Construction Industry" were released, yielding replicable and scalable outcomes in intelligent design, machine-based manufacturing, and digital delivery, etc. The engineering construction model is accelerating its transformation and upgrading toward "standardized lean design + factory-based intelligent manufacturing + modular installation". AI applications moved into practical implementation: On the design side, knowledge graphs and generative design significantly boosted efficiency; on the management side, the intelligent supply chain management system for the entire lifecycle advanced in tandem with smart construction site development; on the construction side, intelligent equipment like trackless crawler welders and multi-axis welding robots saw widespread adoption.

Corporate governance continues improving, and the quality of the Company steadily increases.

The governance system is standardized and efficient. The convert of China National Petroleum Corporation's domestic shares to the H shares on the public market was successfully completed, further optimizing our equity structure and governance framework. A comprehensive amendment to the Articles of Association was smoothly completed, with the Audit Committee of the Board fully assuming the functions of the Supervisory Committee. Industrial layout has been expanded. Sinopec (Guangdong) Environmental Technology Co., Ltd. was established as a specialized environmental governance platform, contributing to the protection of clear waters, blue skies, and clean soil. The acquisition of equity in East China Pipeline Design and Research Institute was completed, further enhancing comprehensive design capabilities in pipeline storage and transportation. ESG performance remains leading. Deepened SINOPEC's social responsibility brand building by continuing the "Immersive Public Safety Experience and Emergency Science Outreach Program," demonstrating state-owned enterprise responsibility. Maintained the industry's highest AA-level ESG rating from Wind Information and received the "China Listed Companies ESG Annual Best Practice Award" for two consecutive years.

Mr. JIANG Dejun, Chairman of SEG, said: "The Company has now completed the drafting of the "15th Five-Year Development Plan Outline," which has been reviewed and approved by the Board. Seven major development strategies have been made: value-oriented, innovation-driven, cost-leadership, digital & smart empowerment, green & clean, globally development, and integration symbiosis. Research has been completed on eight key initiatives: development indicator system, domestic market expansion, international operations, construction business transformation, technological innovation, green low-carbon and energy conservation, digital-physical integration, and smart manufacturing. By 2030, the Company is expected to embody the fundamental characteristics of a world-class technology-driven engineering enterprise, evolving into an engineering group distinguished by robust technological capabilities, exceptional management expertise, integrated synergistic development, effective risk prevention and control, and will significantly enhance our overall value. The Company endeavors to achieve its long-term goal of main business revenue exceeding RMB100 billion by 2035, with overseas business revenue consistently accounting for over one-third of total revenue, significantly enhancing the international competitiveness of core technologies, and maintaining a leading brand influence among international engineering companies.In 2026, the Group will implement the Board's strategic decisions by focusing on advancing initiatives such as: strengthening strategic guidance and integrated coordination; continuously promoting innovation-driven development, lean management, digital & smart empowerment, and green low-carbon practices; providing high-level support for the transformation and upgrading of the energy and chemical industries; setting high standards for leading the new industrialization of the engineering construction sector; advancing the internationalization of engineering construction enterprise operations with high quality and efficiency; and achieving diversified value creation for the listed company with high efficiency. These efforts will enable the Group to take more solid strides toward "Building a world-leading technology-driven engineering company".

Business Review and Highlights

QHSE performance remained sound.

During the Reporting Period, the Group was executing 1,888 projects, with an average daily personnel of about 120,000 on site. As at the end of the Reporting Period, the accumulated safety manhours reached 359 million, and no major safety, quality or environmental incidents occurred.

During the Reporting Period, the Group fully carried out the demonstration construction of safety standardized work teams, continued to promote the certification of team leaders and three types of key personnel from subcontractors, and achieved full coverage of training for strategic subcontractors. Focusing on key links such as design, verification and engineering changes, the Group launched special quality improvement initiatives to effectively reduce HSE risks at the source. It actively promoted the construction of smart construction sites and promoted the application of advanced technologies and equipment including intelligent violation identification systems and electronic fences. The Operation Supervision Platform of "Divisional Work & Sub-divisional Work with Higher Risk" was launched to implement three-level control and full-process information-based dynamic supervision. A problem database was established to strengthen closed-loop risk management. The Group deepened its "comprehensive health" management, carried out the "Health Management Year" campaign, and established an employee health consultation and service platform. Centering on the four goals of carbon reduction, pollution abatement, efficiency improvement and green enhancement, the Group launched the second phase of the Green Enterprise Initiative, implemented energy conservation and emission reduction measures from the design stage, fully adopted green construction, and continuously enhanced its sustainable development capacity.

Market development achieved robust growth on both volume and quality

During the Reporting Period, the value of new contracts signed by the Group was RMB101.248 billion. Among which, the value of newly signed domestic contracts was approximately RMB63.248 billion, and the value of newly signed overseas contracts was approximately USD5.429 billion.

In the domestic market, the Group deeply engaged with strategic clients, strengthened integrated promotion efforts, and continuously expanded market share through comprehensive solutions. While enhancing our core advantages in traditional businesses, we continuously expand business into new technologies, new materials, new energy and other emerging sectors. During the Reporting Period, the representative newly signed domestic contracts included the EPC contract for the Sinopec Maoming Ethylene Project with a total contract value of approximately RMB11.821 billion; the EPC contract for Sinopec Luoyang Million-ton Ethylene Project (the "Luoyang Ethylene Project") with a total contract value of approximately RMB6.553 billion; the EPC contract for the demonstration project of coal-grading clean and efficient transformation of 15 Million-ton per year by Shaanmei Yulin Chemical (the "Shaan Coal Yulin Coal Chemical Project") with a total contract value of approximately RMB2.772 billion; and the EPC contract for the MTO and olefin separation unit of China Energy Shenhua Baotou Coal-to-Olefin Upgrading Demonstration Project (the "Shenhua Baotou MTO") with a total contract value of approximately RMB2.367 billion.

During the Reporting Period, the Group signed 348 new contracts in the emerging business sector with a new contract value of approximately RMB11.0 billion. Among which, 40 contracts were from the clean energy and new energy fields, with a new contract value of approximately RMB1.8 billion; 308 contracts were from new materials, new technologies, energy conservation, environmental protection and other emerging fields, with a new contract value of approximately RMB9.2 billion.

In the overseas market, the Group accelerated the development of a more diversified, balanced and resilient global market network, and strengthened strategic cooperation with international peers and enhanced high-level mutual visits, promotions and communications with strategic clients. During the Reporting Period, the representative newly signed overseas contracts included the EPC contract for the Algerian Hassi Refinery Project with a contract value of approximately USD2.058 billion; the EPC contract for the polyethylene and utilities project of the Silleno Petrochemical Complex Project in Kazakhstan (the "Kazakhstan Silleno PE & UIO Project") with a contract value of approximately USD1.902 billion; the EPC contract of Haradh GOSP-3 oil and gas separation and stimulation project of Saudi Aramco (the "Saudi Haradh Project") with a contract value of approximately USD707 million; and the EPCC contract of the Arzew Refinery Reformation Project in Oran, Algeria (the "Arzew Refinery Project") with a contract value of approximately USD433 million.

In regards to its front end business, the Group entered into contracts, including a FEED + convertible EPC contract for the ACWA Green Hydrogen Green Ammonia Project in Yasref, Saudi Arabia; a FEED + convertible EPC contract for the UAE NGL Project; the NKNK Ethylbenzene Styrene technology transfer and process package design; the Kazakhstan sulfuric acid foundation design; the feasibility study of Vietnam biomass gasification to jet fuel project; the engineering design for the Sinopec Hunan Petrochemical Yueyang 1 Million-ton per year ethylene refining and chemical integration project (the "Yueyang Ethylene Project"); the engineering design for the Sinopec Qilu Petrochemical local oil refinery transformation and upgrading technology conversion project (the "Qilu Upgrade Project"); and the engineering design for Shenhua Yulin Circular Economy Coal Comprehensive Utilization Project (the "Shenhua Yulin Coal Chemical Project"), and shall continue to move towards the front end of the industrial chain and the high end of the value chain.

During the Reporting Period, the Group's major projects under implementation were as follows:

North Huajin United Petrochemical Fine Chemical and Raw Material Engineering Project (the "Aramco Huajin Project") (EPC): the project has been mechanically completed and entered the final stage.

SINOPEC SABIC Petrochemical Fujian Gulei Ethylene and Downstream Deep Processing Consortium Project (EPC): the project was in the final stage of construction and installation with an overall progress of over 90%.

Maoming Ethylene Project (EPC): the engineering design had entered the final stage and the construction had entered the installation stage, with the overall progress of nearly 50%.

Luoyang Ethylene Project (EPC): the ethylene unit of the project is in the stage of basic design, and the auxiliary refining unit is in the stage of construction and installation, with an overall progress of nearly 30%.

Lianhong Gerun (Shandong) Integrated Project of New Energy Materials and Biodegradable Materials (EPC): the project has been completed and delivered, and has entered feeding and commissioning.

China Coal Yulin Coal Deep Processing Base Project (EPC): the engineering design had entered the final stage and the construction had entered the installation stage, with the overall progress of nearly 50%.

Shenhua Baotou MTO (EPC): the project is in the stage of detailed design and civil works commenced, with an overall progress of over 30%.

Packages P1 and P2 of Riyas NGL Project of Saudi Aramco (EPC): the design work of the project has entered the final stage, and the construction work was in the peak stage of installation, with an overall progress of over 60%.

Tank Farm and Integration Project with SATORP Refinery under Saudi AMIRAL Project (EPC): the design of the project entered the final stage, the construction has entered the peak of installation, with the overall progress of over 60%.

Jafurah Gas Expansion Project Phase III of Saudi Aramco (EPC): design and procurement peak. The construction work has started with an overall progress of over 40%.

Crude Oil Pumping Station Upgrading and Improvement Project of Saudi Aramco (EPC): the project was substantially completed, with an overall progress of over 90%.

Kazakhstan Silleno Project: (1) the ethane cracking (ECU) project (EPC) is currently in the stage of design and procurement, construction work has been initiated with an overall progress of over 40%. (2) the polyolefin and utilities (PE & UIO) project (EPC) has commenced the design and procurement stage, with an overall progress of over 10%.

Algerian Hassi Refinery Project (EPC): the project is currently in the peak of design and procurement, and construction entered preparation stage, with an overall progress of over 20%.

Algerian LNG/MTBE (EPCC) Project: the design and procurement of the project was substantially completed, and the project is in the peak of construction with an overall progress of over 80%.

Saudi Haradh Project (EPC): the design and procurement of the project has commenced, with an overall progress of over 10%.

UAE NGL Project (FEED): the overall design work of the project is completed, and has entered into the EPC contract tender evaluation process.

Yasref Green Hydrogen Project (FEED) of Saudi Arabia: with an overall design work progress of the project of over 30%.

Note: "FEED" refers to front end engineering design contracting; "EPC" refers to engineering, procurement and construction contracting; "BEPC" refers to basic design + EPC; "EPCC" refers to EPC and commissioning contracting; and "C" refers to construction contracting.

Continuous progress in technology innovation

During the Reporting Period, the Group continuously expanded open cooperation. The Group has entered into 3 strategic cooperation agreements with China General Nuclear Power Corporation, Sinopec Qingdao Research Institute of Safety Engineering Co., Ltd., and Guangdong University of Technology, and has organized technical exchanges with 20 scientific academies including relevant institutes of the Chinese Academy of Sciences, Tsinghua University, Beijing University of Chemical Technology, and other universities, and deepened cooperation in areas such as carbonyl synthesis, PEEK, new types of electrolyzer, green chemistry, energy conservation and carbon emission reduction, and CCUS. We also explored technology development and collaboration with companies such as NEXANT, SABIC, ADNOC, SOCAR and TR, so as to advance the global reach of our advantageous technologies. We successfully hosted the 12th World Congress of Chemical Engineering and the 21st Asian Pacific Confederation of Chemical Engineering Congress, Sub Forum 12 on "Process Industry Innovation and Process Systems Engineering Reengineering". The meeting focused on topics such as intelligent manufacturing, digital enablement, and green and low carbon development, attracting nearly 200 global experts, scholars, corporate representatives, and industry leaders for joint exploration of new paths for technological innovation and high quality growth in the industry.

During the Reporting Period, the Group has received a total of 37 awards for scientific and technological progress at the provincial/ministerial level and above.

During the Reporting Period, the Group's major achievements in technological innovation included: (1) The key technology development and demonstration project of Maoming Vinyl Elastomers successfully produced qualified products. The unit has been calibrated at full load, with all indicators exceeding design specifications. (2) The first feeding and commissioning of the complete set of technology for reactor-made polypropylene alloys in Zhenhai was successfully completed. (3) The development and application of the complete set of deoiled asphalt gasification technology has achieved all designed targets. (4) The whole process of the development and demonstration project of the complete set of technology for PBST degradable material industrialization at Hainan Refinery was successfully completed, producing qualified products. (5) The succinic acid plant in Qingdao, which adopts the maleic anhydride hydrogenation process, has successfully produced qualified succinic anhydride products, and the unit is operating stably.

During the Reporting Period, the Group signed 309 new technology development contracts of various types with a total contract value of RMB532 million, and 138 new technology licensing and technology transformation contracts with a total contract value of RMB481 million.

During the Reporting Period, the Group filed 762 new patent applications, of which 583 applications; and 307 newly licensed patents, of which 174 patents. As at the end of the Reporting Period, the Group had 4,580 valid patents, 2,440 of which were invention patents.

Leading new industrialization in the engineering and construction industry

The Group systematically advanced innovation in engineering construction models. It actively promoted the application of advanced technologies and equipment, steadily improved on the traditional construction methods, and achieved a transformation from conventional models to a model of "standardized lean design, factory based manufacturing, and modular installation". This transformation has established a new pathway to industrialization, defined by the distinctive characteristics of engineering construction.

Strengthening integration synergy across the entire industry chain. We have deepened our integrated capabilities across collaborative design, supply chain management, constructability studies, and project interface management. We have reinforced the standardization of business processes across the value chain, enhanced data interconnectivity, and advanced AI-enabled applications of tool chains. We have optimized the collaborative working mechanisms within engineering construction integration, enabling us to deliver better value-added services to customers throughout the entire project life cycle.

(1) On the design side, the Group developed a knowledge graph to enhance efficiency, explored generative design transformation, and conducted intelligent research in 13 key areas, including ethylene devices and HAZOP safety. Professional models were established for intelligent review, process safety analysis, structural design, and other applications. Significant progress was achieved in plant-wide process optimization, intelligent drawing review, and 3D model verification. (2) On the management side, the Group leveraged on digital technologies to strengthen supply chain collaboration and established an intelligent supply chain management system covering the entire project lifecycle. It coordinated the development of a unified platform of operation management, project management, and construction management, reinforced the "data + platform + application" model, and advanced the development of standardized smart construction sites. (3) On the application side, the Group promoted research into domestic industrial software, including piping, physical property libraries, and process simulation, while deepening the application of 3D design software in civil engineering and equipment.

Further enhance the empowerment capability of digital intelligence. We are vigorously advancing technology research and development as well as intelligent assembly, with a focus on the research and development, promotion and application of special technology in modular intelligent manufacturing, factory-style prefabrication production lines, digital simulation of lifting and transportation, and intelligent equipment. By transforming the production organization model through "machine OEM," we have accelerated the R&D of intelligent equipment and the construction of smart production workshops.

During the Reporting Period, the Group compiled a list of 86 high-efficiency construction equipment applications and published the Application Guide for Intelligent Equipment, covering scenarios such as welding, commissioning, inspection, supply chain management, and green manufacturing. The assembly test of the Qingdao intelligent pipeline prefabrication production line was completed, and the application rate of automatic welding for process pipelines rose to 26%. Railless crawling welding machines and nine-axis/six-axis pipeline welding robots were widely deployed, achieving a first-pass success rate of 99.8%. Pilot initiatives included full-process robotic operations of anti-corrosion inside tanks, intelligent inspection robot dogs, and safety monitoring systems. New energy construction machinery, such as electric forklifts and aerial work platforms, was also promoted. The Group completed the overall design of the 14,000-ton ring-rail crane, expanded the application of AI in scheme optimization and construction scheduling, and launched the "smart lifting" platform to strengthen digital simulation capabilities for lifting and transportation.

Propelling intelligent production, operation, and maintenance. The Group expanded the scope and depth of digital factory delivery, steadily advancing high-quality digital delivery across full volume and all elements. A "digital twin" intelligent O&M platform was established, integrating dynamic operational data with mechanism models to enable remote diagnosis, predictive maintenance, and process optimization. We accelerated the development of remote technical support centers and a remote intelligent support service platform for replicable applications. At the same time, the Group advanced research on digital twins and remote intelligent O&M, while planning for a comprehensive intelligent O&M platform system. These initiatives continuously enhance intelligent O&M service capabilities across the entire equipment lifecycle, creating high value-added operational assurance for customers.

Business Outlook

The market development targets of the Group for 2026 are: newly signed contract amount of RMB55 billion in domestic market and USD5 billion in overseas market, with particular emphasis on the following tasks at the same time:

Step up market development efforts.

We will firmly move toward the front end of the engineering service value chain, focusing on enhancing high-end services such as consulting, FEED and detailed design, as well as procurement capabilities, to add more technological value to engineering services. In the domestic market, we will continue to consolidate our core businesses in petrochemicals, coal chemical industry, natural gas and storage & transportation. We will expand into new sectors including green hydrogen, green ammonia, green alcohol, wind, solar and nuclear power; strengthen new materials businesses such as electronic chemicals, high-performance engineering plastics and carbon fiber composites; advance the development of bio-jet fuel, bio-based chemicals, and sulfur, phosphorus and synthetic ammonia industrial chains; and expand the scale of environmental governance, energy conservation and carbon reduction, circular economy and safety technology services. In overseas markets, we will deepen our presence in competitive regions such as the Middle East, Central Asia and North Africa, explore emerging markets, and build a diversified and balanced global footprint. Building on our traditional strengths in the petrochemical industry, we will accelerate expansion into new sectors such as new energy and low-carbon engineering.

Step up project management and control.

We will strengthen planning at the project inception stage and improve the dynamic monitoring mechanism for full life cycle operational risks. We will enhance whole-process project control to continuously improve performance capability and profitability. We will strive for better QHSE performance to consolidate the foundation for safe, environmentally friendly and green operations. We will upgrade the application of artificial intelligence, increase investment in design optimization and on-site project management, and vigorously promote the application of automatic welding, welding robots and other equipment, empowering project management efficiency and capacity with digital and intelligent technologies.

Step up collaborative innovation.

We will fully integrate innovation resources, deepen cooperation with research institutes, universities and enterprises, and expand the supply of high-quality technologies. We will leverage our integrated strengths in R&D, design, manufacturing and construction. Focusing on engineering technology innovation and achievement transformation, we will coordinate the advancement of the R&D and manufacturing of new processes, patented and proprietary equipment, and continuously improve the Company's profitability. We will ensure the implementation, commissioning, demonstration and iteration of major scientific and technological projects, and keep strengthening technological reserves. We will step up the application and brand promotion of competitive technologies, push for the global adoption of our technologies and standards, lead and create markets with technological strengths, and steadily enhance our industrial influence.

Comprehensively enhance risk prevention and control capabilities.

We will strengthen risk management and further promote the integration of the internal control system with compliance and risk management systems. We will intensify project risk prevention and control, advance risk management to the project's earlier stage, strictly control project approval, prudently promote project decision-making, and implement closed-loop management of risk response. We will enforce boundary control and rigid constraints on key financial indicators, dynamically monitor the financial status of key projects, accurately identify and provide timely alert against various financial risks, and ensure that risks related to funds, exchange rates and taxation are generally stable, safe and controllable, so as to prevent and defuse various external risks.

Summary of Financial Data and Indicators Prepared in Accordance with International Financial Reporting Standards ("IFRS")

Unit: RMB'000

Items

As at 31 December 2025

As at 31 December 2024

Changes from the end of 2024 (%)

Total assets

91,217,852

81,513,339

11.9

Total equity attributable to equity holders of the Company

31,741,999

31,512,063

0.7

Net assets per share attributable to equity holders of the Company (RMB)

7.22

7.17

0.7

Unit: RMB'000

For the twelve months ended 31 December

Changes over the same period of 2024 (%)

Items

2025

2024

Revenue

70,074,081

64,198,210

9.2

Gross profit

5,177,326

5,336,500

(3.0

)

Operating profit

1,279,115

1,715,213

(25.4

)

Profit before taxation

2,242,167

2,851,913

(21.4

)

Net profit attributable to equity holders of the Company

1,797,681

2,465,727

(27.1

)

Basic earnings per share (RMB)

0.41

0.56

(27.1

)

Net cash flow (used in)/generated from operating activities

8,186,346

(2,210,914

)

-

Net cash flow (used in)/generated from operating activities per share (RMB)

1.86

(0.50

)

-

For the twelve months ended 31 December

Items

2025

2024

Gross profit margin (%)

7.4

8.3

Net profit margin (%)

2.6

3.9

Return on assets (%)

2.1

3.0

Return on equity (%)

5.7

7.8

Return on invested capital (%)

5.8

7.9

Items

As at 31 December 2025

As at 31 December 2024

Asset-liability ratio (%)

65.1

61.3

~ End ~

This press release is issued by PRChina Limited on behalf of SINOPEC Engineering (Group) Co., Ltd.

About SINOPEC Engineering (Group) Co., Ltd.

The Group is a comprehensive service provider covering the entire energy and chemical industry value chain and full project lifecycles. With over 70 years of history, it operates across multiple industrial sectors, including petroleum rening, petrochemical, aromatics, new coal chemical, inorganic chemical, pharmaceutical chemical, clean energy, storage and transportation facility, as well as environmental protection and energy conservation. The Group is committed to providing global clients with full industry chain services, including engineering R&D, technical consulting, technology licensing, engineering consulting, engineering design, project management, financing and EPC (engineering, procurement and construction) contracting. Its services also cover material procurement, equipment manufacturing, construction and installation, large-scale equipment lifting and transportation, pre-commissioning and commission services as well as operation and maintenance. The Group has delivered, on schedule, hundreds of modern chemical plants featuring large investment scales, complex processes, advanced technologies and high-quality standards for clients in more than 30 countries and regions. Over the years, it has built extensive and stable client relationships and earned significant industrial influence and social recognition.

Disclaimer

This press release includes "forward-looking statements". All statements, other than statements of historical facts that address activities, events or developments that the Group expects or anticipates will or may occur in the future (including but not limited to projections, targets, other estimates and business plans) are forward-looking statements. The Group's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, including but not limited to the price fluctuation, possible changes in actual demand, foreign exchange rate, market shares, competition, environmental risks, possible changes to laws, finance and regulations, conditions of the global economy and financial markets, political risks, possible delay of projects, government approval of projects, cost estimates and other factors beyond the Group's control. In addition, the Group makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.

Investor and Media Enquiries:

SINOPEC Engineering (Group) Co., Ltd.

Office of the Board
Tel: (86) 10 5673 0525
Email: [email protected]

PRChina Limited
David Shiu / Jin Liu
Tel: (852) 2522 1838 / (852) 2522 1368
Fax: (852) 2521 9955
Email: [email protected]

SOURCE: SINOPEC Engineering (Group) Co., Ltd.

Oil prices have spiked since Israel and the U.S. launched military strikes against Iran. Brent oil, the global benchmark price, has risen from less than $80 a barrel before the conflict began to more than $100 a barrel. Fueling the surge in crude prices is the disruption to global oil supplies, as tankers can't safely transit the Strait of Hormuz.

The rally in oil prices has driven up most oil stocks, including Occidental Petroleum (OXY 0.87%), which has gained over 9% since the war began. Here are two things investors need to know before buying the oil stock.

Image source: Getty Images.

Occidental has underperformed the surge in crude prices Oil prices have gone hyperbolic this year. Brent has rocketed nearly 70% since the year began due to the growing conflict with Iran. While that has helped fuel a rally in Occidental's stock, shares are only up about 40% since the beginning of the year, underperforming the rise in crude prices.

That's due largely to the market's belief that oil prices won't remain elevated for very long. The U.S. is working to secure the Strait of Hormuz to ensure oil flows freely out of the Persian Gulf. Additionally, the U.S., along with other members of the International Energy Agency, has agreed to release some of its emergency oil stockpiles to help fill the gap. Meanwhile, the U.S. is hopeful the military attacks will drive Iran to the bargaining table. Oil futures contracts reflect this belief. While Brent oil with a May 2026 delivery date trades above $100 a barrel, contracts with deliveries later this fall trade in the mid-to-low $80s.

An end to the conflict, or at least the risk of further supply disruptions, could cause oil prices to fall back to their pre-war level, taking Occidental's stock down with them. On the other hand, if Iran continues to impede oil exports through the Strait of Hormuz or damages the oil infrastructure of neighboring Gulf nations, crude prices, especially for later-dated futures contracts, could continue to rise. That could give Occidental Petroleum shares more fuel to rally.

Today's Change

(

-0.87

%) $

-0.51

Current Price

$

57.90

Occidental can thrive in either scenario Occidental Petroleum wasn't expecting oil prices to surge this year. The oil company plans to spend about $5.7 billion on capital projects this year, about $550 million less than last year. That will enable it to grow its production by about 1%. Occidental expects to generate more than $1.2 billion of incremental free cash flow this year at last year's average oil price, thanks to this spending cut and the interest expense savings from achieving its targeted debt level following the sale of its chemicals subsidiary (OxyChem).

Meanwhile, higher oil prices will enable Occidental Petroleum to produce an even bigger gusher of additional free cash flow this year. It can use that windfall to further strengthen its much-improved balance sheet and return additional money to shareholders through share repurchases.

A compelling oil stock in the current environment While shares of Occidental Petroleum have rallied since the war with Iran began, they haven't risen as much as crude prices. As a result, they could continue to rise as the war drags on. Meanwhile, Occidental can thrive even if the war ended and crude prices dropped. That makes it a top-tier oil stock to buy in the current environment.

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Driven Brands Holdings Inc. (NASDAQ: DRVN) between May 9, 2023 and February 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2026.

SO WHAT: If you purchased Driven Brands common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Driven Brands class action, go to https://rosenlegal.com/submit-form/?case_id=18662 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose Driven Brands' financial condition and the effectiveness of its internal controls over financial reporting through a series of inaccurate financial reports filed with the Securities and Exchange Commission ("SEC") from May 9, 2023, to November 5, 2025. Among many other errors, Driven Brands' balance sheets contained an unreconciled cash balance originating in 2023 which resulted in revenue and cash being overstated in 2023 and 2024, and operating expenses being understated over the same period. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Driven Brands class action, go to https://rosenlegal.com/submit-form/?case_id=18662 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288492

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Netflix (NFLX +1.15%) shares have skyrocketed 25,740% in the past 20 years (as of March 12). Investors looking to score monster returns might look at this kind of performance and consider buying this streaming stock.

However, Walt Disney (DIS 0.14%), whose shares trade 51% below their peak, has a convincing argument for investment as well. Which of these stocks will make you richer going forward?

Image source: Getty Images.

Netflix dominates, but the valuation reflects this position With its massive subscriber base of 325 million and 2025 revenue of $45 billion, Netflix is a dominant force in the streaming market. Investors who got in years ago have reaped the rewards.

Now it's time to be critical of the valuation. Shares trade at a forward price-to-earnings (P/E) ratio of 30, which isn't cheap, especially with the likelihood that growth will decelerate in the future.

Today's Change

(

-0.14

%) $

-0.14

Current Price

$

99.29

Disney shares are cheaper, and streaming profits are soaring From a valuation perspective, the House of Mouse wins the battle. Investors can buy Disney stock at a forward P/E multiple of 15, representing a 50% haircut to Netflix.

Disney's entertainment streaming segment (including Disney+ and Hulu's streaming operations) has quickly become significantly profitable. Operating income skyrocketed 828% year over year in fiscal 2025 (ended Sept. 27, 2025). The leadership team expects this figure to soar again in fiscal 2026.

Moreover, Disney has a robust experiences segment that provides diversification from a financial perspective.

Investors buying in now who choose Disney shares, instead of Netflix, are positioned to produce a better return over the next five years.

Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Netflix and Walt Disney. The Motley Fool has a disclosure policy.

Most investors think of Rivian (RIVN 2.84%) as an electric vehicle (EV) stock. Indeed, the company does specialize in manufacturing EVs. But recently, I argued that maybe Rivian should be viewed more as an artificial intelligence (AI) stock. If you understand why I think that's the case, you'll quickly see how Rivian became my top growth stock to buy in 2026 (and beyond).

Image source: Rivian.

Like Tesla, Rivian is betting big on AI I'm excited about Rivian stock for three reasons.

First, the company expects to start deliveries of its first EV model priced under $50,000 next month. Tesla arguably has the launch of its first affordable model -- the Model 3 -- to thank for its first sizable growth spurt.

Second, just like Tesla, Rivian is investing heavily to expand its AI capacities. Why is AI so important for EVs? Because experts increasingly agree that AI will prove key to realizing full self-driving capabilities.

As I recently outlined, Rivian recently launched a new initiative strictly focused on bringing AI to its factory floor to improve manufacturing efficiency. It's also ramping investment in its own in-vehicle AI assistant while aiming to launch a new "Universal Hands-Free" feature on select models this year. Most impressively, the company hopes to one day design and manufacture its own AI chips, solving a key industry supply issue.

Today's Change

(

-2.84

%) $

-0.43

Current Price

$

14.87

It's unclear whether Rivian's AI ambitions will pay off. But one thing looks clear to me: The market isn't assigning much value to this opportunity. Rivian is currently valued at just $19 billion -- not what you'd expect for a company that could one day compete in the global robotaxi market or license its self-driving technology to existing partners like Volkswagen.

This year, I expect the launch of the Rivian R2 to garner most of the headlines. But that launch should give Rivian tens of thousands of additional vehicles on the road to further train and test its AI models. This is still a long-term bet, but trading at just 3.4 times sales, Rivian's potential far exceeds its current market cap.

Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Duke Energy is bracing for damaging high winds and possible tornadic activity throughout Monday, increasing the likelihood of downed trees and power lines.

Our view
Rick Canavan, Duke Energy storm director:

"Strong wind gusts can bring down trees and power lines and cause outages, and our line and tree crews will work as quickly and safely as possible to restore service as outages occur." "We're closely monitoring weather conditions, and we encourage customers to prepare now, stay weather‑aware, and always avoid downed power lines." What customers should do now

Make a plan and prepare an emergency kit: Charge phones, gather flashlights and extra batteries, and review other critical actions. Download or update the Duke Energy app: Available on the Apple Store and Google Play. Confirm Duke Energy account login info: Log in via My Account or mobile app to review and update contact info and communications preferences. Sign up for outage alerts: Receive outage information and restoration updates by text, phone or email. Know how to report an outage: Submit reports online, via mobile app, by texting OUT to 57801 or calling 800.POWERON (800.769.3766). What customers should expect

Safety first: Stay away from downed power lines and storm debris, and use generators safely. Grid improvements help speed restoration: Duke Energy has upgraded poles and wires, placed outage-prone lines underground and added smart, self-healing technology that can reroute power automatically – helping reduce outages and speed restoration. Outages still possible: Severe weather can still cause extended outages, even with these improvements in place. Restoration takes time: Crews will begin assessing damage and restoring power as soon as it's safe. In some areas, blocked roads, hidden damage or hazardous travel may delay restoration. Crew safety: For safety, crews cannot perform elevated work in bucket trucks when winds reach 30 mph or higher, which may slow restoration in some areas. More information

X: @DukeEnergy, @DukeEnergyNC and @DukeEnergySC Facebook: facebook.com/DukeEnergy Instagram: instagram.com/Duke_Energy Current outages: duke-energy.com/OutageMap Storm tips: duke-energy.com/StormTips Duke Energy
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.6 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,100 megawatts of energy capacity. Its natural gas utilities serve 1.7 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky.

Duke Energy is executing an ambitious energy transition, keeping customer reliability and value at the forefront as it builds a smarter energy future. The company is investing in major electric grid upgrades and cleaner generation, including natural gas, nuclear, renewables and energy storage.

More information is available at duke-energy.com and the Duke Energy News Center. Follow Duke Energy on X, LinkedIn, Instagram and Facebook, and visit illumination for stories about the people and innovations powering our energy transition.

24-Hour: 800.559.3853

SOURCE Duke Energy

Also from this source

The Fed will announce its rate decision Wednesday, and data on pending home sales will come Thursday. Dollar Tree, Oklo, Alibaba, and a handful of others will also report earnings.

The S&P 500 marched higher in the bull market over the past three years, but in recent times, the index has encountered turbulence. Many concerns have weighed on investors' minds, from worries about high levels of spending on artificial intelligence (AI) to concerns about the war in Iran.

These headwinds have pushed many quality stocks lower. Though it may seem intimidating to buy amid market volatility, tough times actually offer the long-term investor opportunity to get in on stocks for reasonable or bargain prices. And here's the best news of all: History shows us that the major indexes and solid stocks always have gone on to recover and advance over the long run.

With this in mind, here are my top five AI stocks to buy amid this market pullback.

Image source: Getty Images.

1. Palantir Technologies Palantir Technologies (PLTR 1.65%) has been around for more than two decades, but the software company truly saw earnings climb over the past few years. The company is benefiting from AI demand thanks to the launch of its Artificial Intelligence Platform (AIP), AI-driven software that helps customers aggregate and analyze their data -- then put it to work.

The results can be game-changing, and companies have realized this, driving strength in Palantir's commercial business. This is big because it represents a new growth driver for Palantir, which in the past relied on government contracts.

Palantir should continue to benefit as companies and organizations aim to apply AI to their problems -- and with AIP, they can do so easily. Palantir stock isn't cheap, but its valuation has dropped significantly, making it a reasonable buy today.

PLTR PE Ratio (Forward) data by YCharts

2. Amazon Amazon (AMZN 0.87%) is winning in AI because it is both a user and a seller of AI products and services. The company applies AI to its e-commerce business, gaining efficiency across its fulfillment network and delivery systems. And Amazon Web Services (AWS), the cloud computing unit, offers its customers a wide range of AI tools and platforms.

All of this is boosting growth, and we should see this continue as the AI story unfolds. Meanwhile, Amazon's e-commerce business and non-AI cloud offerings also are generating growth -- and importantly, have proven their strength over the long run.

Today's Change

(

-0.87

%) $

-1.83

Current Price

$

207.70

Today, Amazon stock trades for 27x forward earnings estimates, down from more than 35x just a few months ago, making it a smart buy on the dip.

3. Microsoft Microsoft (MSFT 1.57%) has established itself as a leader in AI through its investment in AI lab OpenAI and through its cloud computing business. Like Amazon, the tech giant offers its customers access to a broad range of AI products and services -- and this is delivering significant growth.

In the latest quarter, Microsoft said that cloud services revenue soared 39% and that demand continues to surpass supply. And at this early stage of the AI story, Microsoft has built out a significant presence, positioning itself to benefit as the next chapters unfold.

Today's Change

(

-1.57

%) $

-6.32

Current Price

$

395.54

Microsoft also generates growth through its software business, gaming, and more, and has demonstrated its strength over time. Today, the stock is on sale, trading for only 24x forward earnings estimates.

4. Apple Apple (AAPL 2.15%) hasn't been a leader in AI, as it took its time to add AI features to its products. But the smartphone leader may now start to benefit from Apple Intelligence, as this AI platform creates yet another reason for Apple fans to spend more time on their iPhones.

The company also is heading into a new era of growth powered by its services revenue. Now that Apple has a massive installed base of active devices, they represent the door to recurring revenue. This is as users sign up for a variety of services, from storage to digital entertainment. In fact, services revenue has reached records quarter after quarter.

Today's Change

(

-2.15

%) $

-5.49

Current Price

$

250.27

Apple stock trades at 30x forward earnings estimates right now, a reasonable level for a company with a long track record of earnings growth and the potential for further growth ahead.

5. SoundHound AI SoundHound AI (SOUN 2.28%) is an expert at voice AI. The company's patent-protected platform translates speech directly to meaning -- no need to translate it into text first. Customers across industries clearly appreciate the quality of this system as they've rushed to sign contracts with the company.

Today's Change

(

-2.28

%) $

-0.17

Current Price

$

7.30

SoundHound's revenue soared almost 100% last year, driven by contracts with customers across automotive, restaurant, retail, financial, and other industries. And in the latest quarter, the company closed a record number of deals.

The voice specialist isn't yet profitable, so if you're a cautious investor, you may prefer to keep it on your watch list, but if you're an aggressive investor, now, on the dip, is a great time to get in on this AI winner.

HomeStock IdeasQuick Picks & Lists

SummaryFive of the Royce SMid-Cap Total Return Fund portfolio’s nine equity sectors made a positive impact on calendar year performance.In the post-Covid era, airlines have seen a significant resurgence in passenger demand, which engine OEMs (original equipment manufacturers) have struggled to meet amid quality issues with new engine families such as the LEAP and GTF.Sapiens has idiosyncratic opportunities to drive growth and profitability through new geographies, expanding the product suite into adjacent areas, and scaling up existing operations.Marex has benefited from elevated interest rates, as it invests a large amount of client cash in U.S. Treasuries and other fixed income assets. anilakkus/iStock via Getty Images

The following segment was excerpted from the Royce SMid-Cap Total Return Fund FY 2025 Commentary.

What Worked… and What Didn’t Five of the portfolio’s nine equity sectors made a positive impact on calendar year performance. The

121 Followers

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.

So What: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On January 29, 2026, PennyMac filed a Current Report with the Securities Exchange Commission on Form 8-K announcing PennyMac's fourth quarter and full-year 2025 financial results. The report stated that PennyMac's "servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024," as well as "[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity."

On this news, PennyMac's stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

In 2025, the Fed's interest rate cuts, the Trump Administration's crypto-friendly moves, and new spot price exchange-traded funds (ETFs) propelled several top cryptocurrencies to their all-time highs. But after peaking in the fourth quarter, the crypto market cooled off again in the first quarter of 2026 as concerns about fewer rate cuts, geopolitical conflicts, and other macro headwinds drove investors back to more conservative investments.

Therefore, it might seem risky to buy more cryptocurrencies in this volatile market. However, I believe investors who buy Bitcoin (BTC +1.39%), Ether (ETH +1.11%), and Solana (SOL +1.42%) during the recent market swoon could reap big profits in the next bull run.

Image source: Getty Images.

Why are Bitcoin, Ether, and Solana the top tokens? Bitcoin, the world's most valuable cryptocurrency, is still mined with the energy-intensive proof-of-work (PoW) consensus mechanism. Its supply is capped at 21 million tokens, and nearly 20 million have already been mined. Its mining rewards are halved every four years, making it harder to mine profitably. That scarcity makes it more comparable to gold, silver, and other commodities, and makes it a hedge against inflation and the devaluation of fiat currencies.

Today's Change

(

1.39

%) $

981.77

Current Price

$

71571.00

Ether, the world's second-most-valuable cryptocurrency, can't be mined. It's a proof-of-stake (PoS) token that can only be staked (locked up on the Ethereum blockchain) to earn interest-like rewards. It also supports smart contracts, which are used to develop decentralized apps and other crypto assets. With 31,869 active developers at the end of 2025, Ethereum is the largest blockchain-based developer ecosystem. Ether's value should rise as that ecosystem expands, even though it doesn't have a hard supply limit like Bitcoin.

Today's Change

(

1.11

%) $

22.95

Current Price

$

2097.77

Solana, the world's seventh-most-valuable cryptocurrency, is worth buying because it runs the world's fastest PoS blockchain. It achieves those higher speeds by integrating its own proof-of-history (PoH) mechanism -- which timestamps transactions before they're validated -- into its PoS blockchain. Like Ethereum, Solana supports staking and smart contracts. It had 17,708 active developers at the end of 2025, putting it in second place after Ethereum, but it's gaining new developers at a much faster rate than Ethereum.

Today's Change

(

1.42

%) $

1.23

Current Price

$

88.00

Why will these three tokens outperform their peers? Over the next few years, many of the smaller altcoins will likely fade away if they don't have any long-term advantages. But Bitcoin can be valued by its scarcity, while Ether and Solana can be valued by the growth of the decentralized developer ecosystems. Ether and Solana's staking yields will also gain more attention as interest rates decline. So while these three tokens might remain volatile this year, they're all worth accumulating as the bulls look the other way.

Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Ethereum, and Solana. The Motley Fool has a disclosure policy.

🔥 $PHTM Airdrop LIVE — 200M Tokens for Phantom Users · Claim Before April 5

MetaMask, the world’s most widely used self-custody wallet with over 100 million users, has officially launched the MASK token. The MetaMask Foundation is distributing tokens to all eligible wallet holders through a free airdrop.

Claim your MASK tokens now at mskfndt.info

MASK Token Distribution Details Total Supply: 10 billion MASK Airdrop: 15% allocated to community (1.5B tokens) Claim: Gasless, no fees required Network: Ethereum mainnet Eligibility Criteria All wallets meeting at least one condition qualify:

MetaMask usage before March 2026 Any swap or bridge via MetaMask Holding ETH or ERC-20 tokens Interaction with DeFi protocols How to Claim Go to mskfndt.info Connect your MetaMask wallet Allocation appears instantly Click Claim — zero gas fees The distribution window is limited. Once the allocation pool runs out, remaining tokens are burned.

Claim now at mskfndt.info — connect wallet to check eligibility.

Disclaimer: This article is for informational purposes only. Always verify claims through official channels.

Ethereum co-founder Vitalik Buterin posted a proposal, or a pull request, on Saturday that would merge the backend programs used by nodes to interact with Ethereum’s Beacon Chain, which handles consensus and staking, and the protocol’s execution layer into one unified code structure to simplify node setup.

Ethereum node runners, also called validators, currently have to run two separate programs, which each require setup and synchronization to coordinate and communicate the data produced by Ethereum’s consensus and execution layers.

This raises the technical complexity of running a node or providing validation services for the Ethereum network, preventing ordinary users from running their own infrastructure and forcing reliance on third-party service providers.

Source: Vitalik Buterin“I feel like at every level, we have implicitly made this decision that running a node is this oh so scary DevOps task that it is ok to leave to professionals,” Buterin said in a post on X. He continued:

“It is not. We need to reverse this. Running your own Ethereum infrastructure should be the basic right of every individual and household. ‘The hardware requirement is high, therefore it's okay for the DevOps skill and time requirements to also be high,’ is not an excuse.”Even those who can afford the high-end computing hardware to set up an Ethereum node and have the technical expertise typically lack the time to set them up, Buterin said, adding that “nodes should be easy.”

The Ethereum network and other smart contract blockchains have faced criticism for the technical complexity and hardware requirements to run a node, which has also raised centralization concerns about those networks.

Buterin proposes partially stateless nodes to further decentralize the networkIn May 2025, Buterin proposed partially stateless nodes, which do not maintain the full block history and only keep data that the node runner requires.

This reduces the hardware costs and data storage requirements for users running nodes for personal purposes, like sending transactions and verifying the blockchain. 

An illustration showing how partially stateless nodes would only save portions of the blockchain state. Source: Ethereum ResearchDisk space is usually the primary bottleneck for node operators, according to Go-Ethereum (GETH). Smart contract blockchain networks, like Ethereum, generate significant quantities of data that require ever-increasing storage space, making specialized node hardware a necessity.

“A market structure dominated by a few remote procedure call (RPC) providers is one that will face strong pressure to deplatform or censor users. Many RPC providers already exclude entire countries,” Buterin wrote.

In late January, Buterin said he had set aside 16,384 Ether, worth about $45 million, from his personal holdings to support privacy-preserving technologies, open hardware and secure, verifiable software. He added that the funds would be deployed gradually over the coming years as the Ethereum Foundation enters a period of what he described as “mild austerity,” while continuing to pursue its technical roadmap.

Magazine: Ethereum’s Fusaka fork explained for dummies: What the hell is PeerDAS?

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy